Contains Nonbinding Recommendations

Guidance on Carvedilol

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Carvedilol

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 12.5 mg
   Subjects: Normal healthy males and females, general population.
   Additional Comments: Due to safety concerns, the OGD recommends that you conduct the bioequivalence studies using Carvedilol Tablets, 12.5 mg, instead of the 25 mg strength.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 12.5 mg
   Subjects: Normal healthy males and females, general population.
   Additional comments: Please see comment above.

Analytes to measure: Carvedilol and 4-hydroxyphenyl-carvedilol metabolite of Carvedilol in plasma.

Bioequivalence based on (90% CI): Carvedilol.
Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Waiver request of in-vivo testing: 3.125 mg, 6.25 mg, and 25 mg based on (i) acceptable bioequivalence studies on the 12.5 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008